Dara Khalatbari, MD

General Ophthalmologist, Metrolina Eye Associates – North Carolina, USA

Dr. Khalatbari operates at Union West Surgery Center in Indian Trail, NC; and The Surgery Center at Edgewater in Indian Land, SC. He has presented at numerous national meetings in ophthalmology and is the author of numerous publications. He is a contributing author to the Wills Eye Manual, the most widely used ophthalmology text in the world. Dr. Khalatbari is board-certified by the American Board of Ophthalmology.


Q: Have you faced any challenges using ERG/RETeval in a high-volume retina practice?

A: No, the only real challenge we faced was learning our local payor rules for the ERG and VEP tests. Once we learned them, it was easy and we have had no issues with reimbursement since.


Q: Can you name the type of patients you see and explain how you apply our technology in the diagnosis or treatment of their disease?

A: Glaucoma; Cataract;; Drusen/AMD; Diabetic retinopathy; Retinal vascular disease; Optic nerve disease/visual pathway disease (VEP).

Utilizing the RETeval device helps make decisions on whether to treat or not, when to see the patient back and if an upgraded cataract surgery is necessary or not, among other uses.


Q: Would you recommend the RETeval to your colleagues and why?

A: Yes! Amazing product. Easy to use. Improves patient care. Advances the science of medicine.


Q: How long did it take you to recover your investment and why did you decide to add more than one RETeval to your practice?

A:Recovering the investment took about 4-6 months per device. We have 6 locations and are happy to share that we have now one device per location. All of our docs love the device, so we needed multiple to keep us from fighting over them.


Q: From your experience, what are the key points that justify the investment on RETeval?

A: For me, the key points that justify the investment are that the device is easy to use, reliable, the results are easy to interpret, and that it improves patient care.


Q: In what ways does RETeval contribute to your decision making regarding treating a patient?

A: It contributes in different ways. I’d like to give you some examples:

1.) If a patient has an abnormal ERG, I may limit my discussion about premium cataract surgery.

2.) If a patient has a borderline looking retina from diabetic retinopathy but a totally normal and symmetrical ERG, I may see that patient back a little later than otherwise, or sooner if ERG is abnormal.

3) It also helps guide MIGS decisions for borderline glaucoma patients.


Q: What are your favorite features of the RETeval and why are they important?

A: The device is portable and can be used anywhere. At the same time, it’s easy to use with minimal technical expertise which allows our new testing techs to pick-it up very quickly.

It’s reproducible, fast, relevant and makes the test valuable for a high-volume practice.


 Q: How long did it take you to get your technicians to learn how to operate the device?

A: It took them about 2 tests. Seriously, it is super intuitive and easy to operate.


Q: What are your thoughts on LKC’s Sensor strip electrodes?

A: LKC’s electrodes are easier to use and more comfortable for the patient than any other ERG electrodes we have used or seen and that is remarkable.


Q: How important is it to you and to your patients that the device is non-invasive?

It is very important as it is easy on the patient and they don’t mind it at all. They think it’s neat and want to learn more about the technology and that’s why I don’t think twice about ordering it on any patient.